PriceSensitive

AREV Life Sciences (CSE:AREV) completes lab and fungi fruiting room build

Psychedelics
CSE:AREV
23 February 2022 13:15 (EDT)

AREV Life Sciences Global Corp. (AREV) has completed its fungi inoculation lab, colonizing and fruiting rooms.

The fruiting room has been populated with colonized blocks of Lion’s Mane (Hericium erinaceus) containing bioactive substances with beneficial effects on the body, especially the brain, heart and gut.

Over the past three months, AREV has been building its fungi spore lab, colonizing and fruiting rooms at its Coquitlam facility.

With this phase now complete, AREV is successfully extracting 10 per cent herricium from the lion’s mane mushrooms utilizing a modified method of its existing extraction technology.

The 10 per cent yield is considered exceptional by mycology experts and AREV’s JV partner Absolem Health, which is collaborating on commercializing the resulting extract.

“This is another milestone achieved by the team. The fresh product and extract serve as an additional revenue stream providing a strategic and versatile raw material supply source for finished products,” said Mike Withrow, CEO of AREV Life Sciences.

“AREV is prepared for the wide potential utilization of these innovative extracts and compounds created from our proprietary technologies as these materials may be sold for use in natural health products and also can be fractionated into small molecules for drug development,” added Withrow.

Lion’s mane mushrooms contain powerful antioxidant and anti-inflammatory compounds that may help reduce the impact of chronic illnesses.

Lion’s mane mushrooms have been found to contain compounds that may stimulate the growth of brain cells and protect those cells from damage caused by Alzheimer’s disease.

Studies also suggest lion’s main mushrooms may relieve mild symptoms of anxiety and depression.

The compounds are seen to protect against stomach and intestinal ulcers in rodents and speed up the recovery time from nervous system injuries in rodents.

AREV Life Sciences Global Corp. is a fully integrated, publicly traded, early-stage life science enterprise dedicated to delivering therapeutic interventions to public health through the extraction of unique compounds, discovery, innovation and successful collaborations.

AREV Life Sciences Global Corp. (AREV) is down 17.54 per cent, trading at C$0.24 at 11:35 am EST.

Related News